The DOI matches its Crossref record; 212 of the 212 references it cites were found in a registry or an index.
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication
Open accessAbstract
Summary: The continual interaction of the immune system with a developing tumor is thought to result in the establishment of a dynamic state of equilibrium. This equilibrium depends on the balance between effector and regulatory T‐cell compartments. Whereas regulatory T cells can infiltrate and accumulate within tumors, effector T cells fail to efficiently do so. Furthermore, effector T cells that do infiltrate the tumor become tightly controlled by different regulatory cellular subsets and inhibitory molecules. The outcome of this balance is critical to survival, and whereas in some cases the equilibrium can rapidly result in the elimination of the transformed cells by the immune system, in many other cases the tumor manages to escape immune control. In this review, we discuss relevant work focusing on the establishment of the intratumor balance, the dynamic changes in the populations of effector and regulatory T cells within the tumor, and the role of the tumor vasculature and its activation state in the recruitment of different T‐cell subsets. Finally, we also discuss work associated to the manipulation of the immune response to tumors and its impact on the infiltration, accumulation, and function of tumor‐reactive lymphocytes within the tumor microenvironment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–212 of 212
Spaapen, R. M., Lokhorst, H. M., van den Oudenalder, K., Otterud, B., Dolstra, H., Leppert, M., Minnema, M. C., Bloem, A. C., & Mutis, T. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080713 · Cited by 61
Hermans, I. F., Daish, A., Yang, J., Ritchie, D., & Ronchese, F. (1998) · PubMed · Cited by 60
Bioley, G., Jandus, C., Tuyaerts, S., Rimoldi, D., Kwok, W. W., Speiser, D. E., Tiercy, J., Thielemans, K., Cerottini, J., & Romero, P. J. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.10.6769 · Cited by 60
Hamzah, J., Nelson, D. J., Moldenhauer, G., Arnold, B., Hämmerling, G. J., & Ganß, R. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33201 · Cited by 57
Thompson, R. H., Webster, W. S., Cheville, J. C., Lohse, C. M., Dong, H., Leibovich, B. C., Kuntz, S. M., Sengupta, S., Kwon, E. D., & Blute, M. L. (2005) · Urology · doi:10.1016/j.urology.2005.06.010 · Cited by 55
Hamzah, J., Altin, J. G., Herringson, T. P., Parish, C. R., Hämmerling, G. J., O’Donoghue, H., & Ganß, R. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900736 · Cited by 49
Reardon, C., Wang, A., & McKay, D. M. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.12.8316 · Cited by 46
Chen, H. (2010) · International Journal of Oncology · doi:10.3892/ijo_00000561 · Cited by 42
Interaction of Regulatory T Cells with Antigen-Presenting Cells in Health and Disease
Mahnke, K., Ring, S., Bedke, T., Karakhanova, S., & Enk, A. (2008) · Chemical immunology/Fortschritte der Allergielehre/Progress in allergy/Chemical immunology and allergy · doi:10.1159/000154854 · Cited by 30
Gritzapis, A. D., Voutsas, I. F., Lekka, E., Papamichail, M., & Baxevanis, C. N. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2517 · Cited by 27
Holloway, P. A., Kaldenhoven, N., Kok, H., van Dijk, M., Otten, H. G., Tilanus, M. G. J., Postma, S. M., Mutis, T., Lokhorst, H. M., & Bloem, A. C. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05283.x · Cited by 20
Corthay, A. (2007) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-34814-8_14 · Cited by 15
Cited by
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974
“…support for the clinical observations that (a) checkpoint blockade therapy amplifies, in some cases, pre-existing anti-tumour T cell responses 8,9,21,22 ; (b) whereas α CTLA-4 treatment eliminates Tregs, promotes T cell priming, and renders the host more susceptible to autoimmunity 13,22,23…”
Self-citationSimpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J. Y., Yagita, H., Wolchok, J. D., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130579 · Cited by 1,472
“Antibody-mediated depletion can occur via complementmediated lysis (Reff et al., 1994; Giorgini et al., 2008; Wang and Weiner, 2008) or antibody-dependent cell-mediated cytotoxicity (ADCC; Swanson and Hoppe, 2004; Stuart and Ezekowitz, 2005; Nimmerjahn and Ravetch, 2008).”
BackgroundInfluentialSelf-citationHuang, Y., Yuan, J., Righi, E., Kamoun, W. S., Ancukiewicz, M., Nezivar, J., Santosuosso, M., Martin, J. D., Martin, M. R., Vianello, F., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1215397109 · Cited by 1,099
Skoulidis, F., Byers, L. A., Diao, L., Papadimitrakopoulou, V. A., Tong, P., Izzo, J., Behrens, C., Kadara, H., Parra, E. R., Canales, J. R., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1236 · Cited by 936
Self-citationOncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia
Pylayeva-Gupta, Y., Lee, K. E., Hajdu, C. H., Miller, G., & Bar-Sagi, D. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.04.024 · Cited by 721
“Moreover, there is growing evidence that targeting the tumor immune microenvironment may provide an effective therapeutic strategy (Quezada et al., 2011).”
Background
Metadata
- Authors
- Quezada, S. A., Peggs, K. S., Simpson, T. R., & Allison, J. P.
- Venue
- Immunological Reviews
- Publisher
- Wiley
- Published
- 2011-04-13
- Volume
- 241
- Issue
- 1
- Pages
- 104-118
- ISSN
- 0105-2896 (ISSN-L)
- 1600-065X
- OpenAlex
- W1881296535
- Cited by
- 276
- References
- 212
- FWCI
- 3.12
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.